Marc Mansour

982 total citations
37 papers, 703 citations indexed

About

Marc Mansour is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Marc Mansour has authored 37 papers receiving a total of 703 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Immunology, 16 papers in Molecular Biology and 13 papers in Oncology. Recurrent topics in Marc Mansour's work include Immunotherapy and Immune Responses (30 papers), Cancer Immunotherapy and Biomarkers (10 papers) and vaccines and immunoinformatics approaches (10 papers). Marc Mansour is often cited by papers focused on Immunotherapy and Immune Responses (30 papers), Cancer Immunotherapy and Biomarkers (10 papers) and vaccines and immunoinformatics approaches (10 papers). Marc Mansour collaborates with scholars based in Canada, United States and Belgium. Marc Mansour's co-authors include Genevieve Weir, Mohan Karkada, Robert Liwski, Neil L. Berinstein, Robert G. Brown, Marianne M. Stanford, Bill Pohajdak, Lisa D. MacDonald, Pirouz Daftarian and W. Martin Kast and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Marc Mansour

37 papers receiving 685 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marc Mansour Canada 16 470 240 239 113 53 37 703
Genevieve Weir Canada 14 322 0.7× 183 0.8× 175 0.7× 99 0.9× 47 0.9× 37 529
Cynthia M. Fehres Netherlands 13 556 1.2× 106 0.4× 302 1.3× 73 0.6× 70 1.3× 29 750
Marcela Alcántara‐Hernández United States 13 630 1.3× 150 0.6× 192 0.8× 51 0.5× 31 0.6× 18 842
Eryn Blass United States 9 797 1.7× 397 1.7× 432 1.8× 71 0.6× 75 1.4× 12 1.1k
Pamela K. Norberg United States 10 264 0.6× 284 1.2× 202 0.8× 163 1.4× 26 0.5× 19 661
Thomas Démoulins Switzerland 17 584 1.2× 121 0.5× 530 2.2× 78 0.7× 43 0.8× 31 948
Benjamin Claass Germany 5 401 0.9× 69 0.3× 291 1.2× 85 0.8× 15 0.3× 5 650
Mariana O. Diniz United Kingdom 17 452 1.0× 165 0.7× 252 1.1× 188 1.7× 14 0.3× 32 743
Angelino T. Tromp Netherlands 6 339 0.7× 126 0.5× 225 0.9× 30 0.3× 27 0.5× 9 460
Kimberly Denis-Mize United States 14 488 1.0× 89 0.4× 320 1.3× 127 1.1× 71 1.3× 20 963

Countries citing papers authored by Marc Mansour

Since Specialization
Citations

This map shows the geographic impact of Marc Mansour's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Mansour with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Mansour more than expected).

Fields of papers citing papers by Marc Mansour

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc Mansour. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Mansour. The network helps show where Marc Mansour may publish in the future.

Co-authorship network of co-authors of Marc Mansour

This figure shows the co-authorship network connecting the top 25 collaborators of Marc Mansour. A scholar is included among the top collaborators of Marc Mansour based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc Mansour. Marc Mansour is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Phares, Timothy W., Vinayaka Kotraiah, Deshapriya S. Karunarathne, et al.. (2020). A Peptide-Based PD1 Antagonist Enhances T-Cell Priming and Efficacy of a Prophylactic Malaria Vaccine and Promotes Survival in a Lethal Malaria Model. Frontiers in Immunology. 11. 1377–1377. 7 indexed citations
2.
Kotraiah, Vinayaka, Timothy W. Phares, Cecille D. Browne, et al.. (2020). Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics. Frontiers in Immunology. 11. 264–264. 25 indexed citations
3.
Weir, Genevieve, Mohan Karkada, David W. Hoskin, et al.. (2017). Combination of poly I:C and Pam3CSK4 enhances activation of B cells in vitro and boosts antibody responses to protein vaccines in vivo. PLoS ONE. 12(6). e0180073–e0180073. 25 indexed citations
4.
Berinstein, Neil L., Matthew C. Cheung, Rena Buckstein, et al.. (2016). A phase 2 clinical trial testing DPX-Survivac and metronomic low dose cyclophosphamide as immunotherapy for patients with recurrent diffuse large b-cell lymphoma.. Journal of Clinical Oncology. 34(15_suppl). e14578–e14578. 3 indexed citations
5.
DeBay, Drew R., Kimberly Brewer, Genevieve Weir, et al.. (2015). Using MRI to evaluate and predict therapeutic success from depot-based cancer vaccines. Molecular Therapy — Methods & Clinical Development. 2. 15048–15048. 5 indexed citations
6.
Weir, Genevieve, Marianne M. Stanford, Neil L. Berinstein, et al.. (2014). Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response. OncoImmunology. 3(8). e953407–e953407. 29 indexed citations
7.
Karkada, Mohan, Marc Mansour, & Neil L. Berinstein. (2014). Therapeutic vaccines and cancer: focus on DPX-0907. Biologics. 8. 27–27. 40 indexed citations
8.
Brewer, Kimberly, Nicole A. Pelot, Marianne M. Stanford, et al.. (2014). Clearance of depot vaccine SPIO-labeled antigen and substrate visualized using MRI. Vaccine. 32(51). 6956–6962. 21 indexed citations
9.
10.
Berinstein, Neil L., Amit M. Oza, Kunle Odunsi, et al.. (2013). Effect of oral cyclophosphamide on the immunogenicity of DPX-Survivac in ovarian cancer patients: Results of a phase I study.. Journal of Clinical Oncology. 31(15_suppl). 3030–3030. 6 indexed citations
11.
Mansour, Marc, et al.. (2012). Development and validation of an HPLC/UV assay for separation and quantification of peptide antigens from a liposomal vaccine delivery platform. Journal of Pharmaceutical and Biomedical Analysis. 66. 176–182. 10 indexed citations
12.
Berinstein, Neil L., Mohan Karkada, Michael A. Morse, et al.. (2012). First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. Journal of Translational Medicine. 10(1). 156–156. 68 indexed citations
13.
Mansour, Marc. (2010). Next generation of therapeutic cancer vaccines require smart vaccine design. Human Vaccines. 6(12). 959–961. 1 indexed citations
14.
Karkada, Mohan, Genevieve Weir, Lisa D. MacDonald, et al.. (2010). A Novel Breast/Ovarian Cancer Peptide Vaccine Platform That Promotes Specific Type-1 but not Treg/Tr1-type Responses. Journal of Immunotherapy. 33(3). 250–261. 27 indexed citations
15.
MacDonald, Lisa D., et al.. (2010). Efficacy of a single dose hepatitis B depot vaccine. Vaccine. 28(44). 7143–7145. 10 indexed citations
16.
17.
Daftarian, Pirouz, Marc Mansour, Bill Pohajdak, et al.. (2007). Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax® encapsulated CTL/T helper peptides. Journal of Translational Medicine. 5(1). 26–26. 33 indexed citations
18.
19.
Levy, Julie K., Marc Mansour, P. Cynda Crawford, Bill Pohajdak, & Robert G. Brown. (2005). Survey of zona pellucida antigens for immunocontraception of cats. Theriogenology. 63(5). 1334–1341. 23 indexed citations
20.
Rand, ML, Jeffrey S. Warren, Marc Mansour, Walter Newman, & D J Ringler. (1996). Inhibition of T cell recruitment and cutaneous delayed-type hypersensitivity-induced inflammation with antibodies to monocyte chemoattractant protein-1.. PubMed. 148(3). 855–64. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Genevieve Weir Breakdown of academic impact, for papers by Cynthia M. Fehres Breakdown of academic impact, for papers by Marcela Alcántara‐Hernández Breakdown of academic impact, for papers by Eryn Blass Breakdown of academic impact, for papers by Pamela K. Norberg Breakdown of academic impact, for papers by Thomas Démoulins Breakdown of academic impact, for papers by Benjamin Claass Breakdown of academic impact, for papers by Mariana O. Diniz Breakdown of academic impact, for papers by Angelino T. Tromp Breakdown of academic impact, for papers by Kimberly Denis-Mize
Rankless by CCL
2026